Tumor Models Archives - Page 6 of 10

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an...

Osimertinib-Resistant Cell Lines and Models

Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug. ...

Enhertu-Induced Resistant Tumor Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages...

Metastasis-Related In Vitro Assays and Xenograft Models

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis. To support research in this field, WuXi AppTec offers...

Oncolytic Virus Platform

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell...

Evaluation Platform for Bispecific Antibodies

WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs). Our comprehensive...

Enzalutamide-resistant LNCaP ARF877L Mutation KI model

We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An...

Tumor Cell Panel | Screening Services

Comprehensive cell line screening assays integrated with downstream pharmacological services Cell panel of 600+ human cancer cell lines for single...

Knowledge Library